Peer-reviewedCC BYBlood cancer journal
Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study.
15 affiliations
- 1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA. [email protected].
- 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
- 3Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
- 4Division of Hematology, Sylvester Comprehensive Cancer Center, Department of Medicine, University of Miami, Miami, FL, USA.
- 5Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
- 6Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
- 7Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
- 8Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA.
- 9Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
- 10Genentech, Inc, South San Francisco, CA, USA.
- 11Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 12Division of Hematology, Oncology, and Bone & Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
- 13Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- 14Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 15CommonSpirit Health, Durango, CO, USA.
Abstract
Treatment strategies for relapsed/refractory large B-cell lymphoma (R/R LBCL) have evolved rapidly, yet relationships between therapy selection and outcomes remain poorly defined. The LEO CReWE study evaluated disease characteristics, patterns of care, and outcomes in 1504 patients with R/R LBCL from 2002 to 2022. Of these, 64% received chemoimmunotherapy at second-line (2L). Autologous stem cell transplant (ASCT) and/or chimeric antigen receptor T-cell therapy (CAR-T) were planned at 2L for 984 patients (65%), with 471 (31%) ultimately receiving ASCT and 94 (6%) receiving CAR-T. Complete response (CR) rates at 2L ranged from 24% for lenalidomide-based regimens to 49% for CAR-T; salvage chemotherapy achieved a 44% CR rate overall and 60% among patients who eventually underwent ASCT. Median event-free and overall survival from 2L were 4.3 months and 18.3 months, respectively; survival improved in eras during which CAR-T was available. Patients intended for but unable to receive ASCT or CAR-T experienced poor outcomes comparable to those never intended for curative therapy at 2L. The LEO CReWE study represents the first large-scale depiction of 2L treatment patterns and outcomes for LBCL in the modern era, inclusive of all treatment approaches, and underscores the ongoing need for more effective therapies despite the advent of CAR-T.
Related
- Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States.
- Treatment patterns and safety outcomes after splenectomy or thrombopoietin receptor agonists as second-line therapy for immune thrombocytopenia: Korean claims-based study.
- Real-World Clinical Outcomes and Treatment Patterns in Patients with Unresectable Stage III NSCLC Treated with CCRT With or Without Durvalumab as Consolidation Therapy: A Retrospective Cohort Study
- Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA
- Real‐World Treatment Patterns, Burden of Illness, and Survival of Autologous Stem Cell Transplant‐Ineligible Patients With Mantle Cell Lymphoma in Ontario, Canada
BibTeX
@article{koff2026treatment,
title = {{Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study.}},
author = {Jean L Koff and Melissa C Larson and Jonathon B Cohen and Izidore S Lossos and Peter Martin and Thomas M Habermann and Carla Casulo and Samuel Yamshon and Andrea Lo-Rossi and Ashwini Shewade and Connie Lee Batlevi and Anthony Masaquel and Yong Mun and Yucai Wang and Arushi Khurana and Grzegorz S Nowakowski and Dai Chihara and Eric Mou and Umar Farooq and Dilan Patel and Amy Ayers and Tanner W Reicks and James R Cerhan and Christopher R Flowers and Matthew J Maurer and Loretta J Nastoupil},
journal = {Blood cancer journal},
year = {2026},
month = jul,
doi = {10.1038/s41408-026-01563-2},
url = {https://europepmc.org/article/MED/42897159},
note = {CC BY},
}
RIS
TY - JOUR
TI - Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study.
AU - Jean L Koff
AU - Melissa C Larson
AU - Jonathon B Cohen
AU - Izidore S Lossos
AU - Peter Martin
AU - Thomas M Habermann
AU - Carla Casulo
AU - Samuel Yamshon
AU - Andrea Lo-Rossi
AU - Ashwini Shewade
AU - Connie Lee Batlevi
AU - Anthony Masaquel
AU - Yong Mun
AU - Yucai Wang
AU - Arushi Khurana
AU - Grzegorz S Nowakowski
AU - Dai Chihara
AU - Eric Mou
AU - Umar Farooq
AU - Dilan Patel
AU - Amy Ayers
AU - Tanner W Reicks
AU - James R Cerhan
AU - Christopher R Flowers
AU - Matthew J Maurer
AU - Loretta J Nastoupil
PY - 2026
DA - 2026/07/01
JO - Blood cancer journal
DO - 10.1038/s41408-026-01563-2
UR - https://europepmc.org/article/MED/42897159
AB - Treatment strategies for relapsed/refractory large B-cell lymphoma (R/R LBCL) have evolved rapidly, yet relationships between therapy selection and outcomes remain poorly defined. The LEO CReWE study evaluated disease characteristics, patterns of care, and outcomes in 1504 patients with R/R LBCL from 2002 to 2022. Of these, 64% received chemoimmunotherapy at second-line (2L). Autologous stem cell transplant (ASCT) and/or chimeric antigen receptor T-cell therapy (CAR-T) were planned at 2L for 984 patients (65%), with 471 (31%) ultimately receiving ASCT and 94 (6%) receiving CAR-T. Complete response (CR) rates at 2L ranged from 24% for lenalidomide-based regimens to 49% for CAR-T; salvage chemotherapy achieved a 44% CR rate overall and 60% among patients who eventually underwent ASCT. Median event-free and overall survival from 2L were 4.3 months and 18.3 months, respectively; survival improved in eras during which CAR-T was available. Patients intended for but unable to receive ASCT or CAR-T experienced poor outcomes comparable to those never intended for curative therapy at 2L. The LEO CReWE study represents the first large-scale depiction of 2L treatment patterns and outcomes for LBCL in the modern era, inclusive of all treatment approaches, and underscores the ongoing need for more effective therapies despite the advent of CAR-T.
SN - 2044-5385
ER -